Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Candesartan Cilexetil and Hydrochlorothiazide Tablets USP in the strengths of 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg. The drug combines an angiotensin II receptor (type ATI) antagonist and a diuretic, hydrochlorothiazide and is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 175 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
